サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1701666

自家調整検査（LDT）の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）

Laboratory Developed Test Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 319 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
自家調整検査（LDT）の世界市場：産業分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年04月08日
発行: Persistence Market Research
ページ情報: 英文 319 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な調査結果

  • 自家調整検査（LDT）の市場規模：90億米ドル（2025年）
  • 予測される市場金額：139億米ドル（2032年）
  • 世界市場の成長率：6.4%（2025年～2032年のCAGR）

自家調整検査（LDT）市場 - レポート範囲

自家調整検査（LDT）市場には、単一の研究所内で設計、製造、使用される診断検査が含まれます。これらの検査は、商業的に利用可能な代替品が存在しない場合に特に重要であり、独自の患者集団や新たな健康上の脅威に合わせたソリューションを提供します。LDTは、腫瘍、遺伝、感染症、希少疾患などの特殊な診断分野で広く使用されています。個別化医療に対する需要の高まり、慢性疾患や感染症の流行、分子診断の技術的進歩が市場成長の主な要因となっています。

市場成長の促進要因

複数の要因が世界の自家調整検査（LDT）市場の成長を促進しています。個別化医療の急速な進行とカスタマイズされた診断ソリューションへのニーズが、LDTの利用を後押ししています。特に分子診断と次世代シーケンシングにおける技術の進歩は、これらの検査の速度、精度、信頼性を著しく向上させています。さらに、がん、遺伝性疾患、感染症の世界的な負担の増大は、専門的で柔軟な診断オプションに対する需要を増幅させています。COVID-19パンデミックは、迅速で適応性の高い診断ツールの重要性をさらに浮き彫りにし、LDTに対する認識と規制当局の支持を促進しました。診断研究への投資の増加や、新規アッセイの開発における学術研究機関の役割の増大も、市場の前進を後押ししています。

市場抑制要因

その利点にもかかわらず、自家調整検査（LDT）市場は複数の課題に直面しています。主な懸念は、地域間で規制監督が統一されていないことであり、これが検査の品質や患者の安全性にばらつきをもたらす可能性があります。今後予定されている規制の変更、特に米国で提案されているVALID Actに基づく規制の変更は、検査施設により厳しいコンプライアンス負担を課し、経営コストを増加させ、技術革新を制限する可能性があります。さらに、LDTは多くの場合、多大な専門知識とインフラを必要とするため、特にリソースの少ない環境では、その普及が制限されます。再現性、バリデーション、標準化に関する懸念は、広範な採用をさらに妨げます。最後に、FDAが承認した商業検査との競合により、特定の用途におけるLDTの市場シェアが低下する可能性があります。

市場機会

LDT市場は、診断における継続的な技術革新と精密医療の拡大により、大きな成長機会をもたらしています。臨床検査へのAIとバイオインフォマティクスの統合が進むことで、より正確で効率的な検査開発への新たな可能性が生まれます。特にアジア太平洋やラテンアメリカなどの新興経済圏では、医療インフラや診断能力が向上しており、LDT採用の新たな道が開かれつつあります。さらに、疾患の早期発見や標的治療の需要が高まる中、LDTは希少疾患や薬理ゲノミクスなどのニッチ診断分野で中心的な役割を果たす好ましい立場にあります。また、学術研究センターと商業診断企業の提携は、LDT開発と市場での活動範囲を加速させる可能性があります。

当レポートでは、世界の自家調整検査（LDT）市場について調査し、成長促進要因、動向、機会、課題などの市場力学の詳細な分析を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 主要動向
  • マクロ経済要因
    • 世界の部門の見通し
    • 世界のGDP成長の見通し
  • COVID-19の影響の分析
  • 予測要因 - 関連性と影響

第3章 付加価値考察

  • 製品採用分析
  • 規制情勢
  • 償還シナリオ
  • PESTLE分析
  • プロモーション戦略：主要企業別

第4章 世界の自家調整検査（LDT）の見通し

  • 主なハイライト
    • 市場規模と前年比成長
    • 絶対的収益機会
  • 市場規模の分析と予測
    • 市場規模の実績の分析（2019年～2024年）
    • 現在の市場規模の分析と予測（2025年～2032年）
  • 世界の自家調整検査（LDT）の見通し：検査タイプ
    • イントロダクション/主な調査結果
    • 市場規模の実績の分析：検査タイプ別（2019年～2024年）
    • 現在の市場規模の分析と予測：検査タイプ別（2025年～2032年）
    • 市場の魅力分析：検査タイプ
  • 世界の自家調整検査（LDT）の見通し：用途
    • イントロダクション/主な調査結果
    • 市場規模の実績：用途別（2019年～2024年）
    • 現在の市場規模の分析と予測：用途別（2025年～2032年）
    • 市場の魅力分析：用途
  • 世界の自家調整検査（LDT）の見通し：エンドユーザー
    • イントロダクション/主な調査結果
    • 市場規模の実績：エンドユーザー別（2019年～2024年）
    • 現在の市場規模の分析と予測：エンドユーザー別（2025年～2032年）
    • 市場の魅力分析：エンドユーザー

第5章 世界の自家調整検査（LDT）の見通し：地域

  • 主なハイライト
  • 市場規模の実績の分析：地域別（2019年～2024年）
  • 現在の市場規模の分析と予測：地域別（2025年～2032年）
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の自家調整検査（LDT）の見通し

第7章 欧州の自家調整検査（LDT）の見通し

第8章 東アジアの自家調整検査（LDT）の見通し

第9章 南アジア・オセアニアの自家調整検査（LDT）の見通し

第10章 ラテンアメリカの自家調整検査（LDT）の見通し

第11章 中東・アフリカの自家調整検査（LDT）の見通し

第12章 競合情勢

  • 市場シェア分析（2025年）
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル（詳細 - 概要、財務、戦略、近年の発展）
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Kaneka Eurogentec SA
    • Vastian
    • Roche Diagnostics
    • Adaptive Biotechnologies.
    • Guardant Health, Inc.
    • Smiths Medical
    • Quest Diagnostics
    • Beckman Coulter
    • OPKO Health, Inc.
    • Siemens Medical Solutions USA, Inc.
    • Quanterix
    • Proteomics International

第13章 付録

目次
Product Code: PMRREP3430

Persistence Market Research has recently released a comprehensive report on the global Laboratory Developed Test (LDT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Laboratory Developed Test Market Size (2025E): US$ 9.0 Bn
  • Projected Market Value (2032F): US$ 13.9 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.4%

Laboratory Developed Test Market - Report Scope:

The Laboratory Developed Test (LDT) market encompasses diagnostic tests that are designed, manufactured, and used within a single laboratory. These tests are particularly vital when no commercially available alternatives exist, providing solutions tailored for unique patient populations or emerging health threats. LDTs are widely used in specialized diagnostic areas such as oncology, genetics, infectious diseases, and rare disorders. The increasing demand for personalized medicine, rising prevalence of chronic and infectious diseases, and technological advancements in molecular diagnostics are key contributors to market growth.

Market Growth Drivers:

Several key factors are fueling the growth of the global Laboratory Developed Test market. The rapid rise in personalized medicine and the need for customized diagnostic solutions are encouraging the use of LDTs. Technological advancements, especially in molecular diagnostics and next-generation sequencing, have significantly improved the speed, accuracy, and reliability of these tests. Moreover, the growing burden of cancer, genetic disorders, and infectious diseases globally has amplified the demand for specialized and flexible diagnostic options. The COVID-19 pandemic further highlighted the importance of rapid and adaptable diagnostic tools, driving both awareness and regulatory support for LDTs. Increasing investments in diagnostic research and the growing role of academic and research institutions in developing novel assays also propel the market forward.

Market Restraints:

Despite their advantages, the Laboratory Developed Test market faces several challenges. A key concern is the lack of uniform regulatory oversight across regions, which can lead to variability in test quality and patient safety. The upcoming regulatory changes, particularly in the United States under the proposed VALID Act, could impose stricter compliance burdens on labs, increasing operational costs and limiting innovation. In addition, LDTs often require significant expertise and infrastructure, restricting their widespread use, especially in low-resource settings. Concerns around reproducibility, validation, and standardization further hinder broader adoption. Lastly, competition from FDA-approved commercial tests can reduce the market share for LDTs in certain applications.

Market Opportunities:

The LDT market offers substantial growth opportunities driven by continued innovation in diagnostics and the expanding scope of precision medicine. The increasing integration of artificial intelligence and bioinformatics into laboratory testing presents new possibilities for more accurate and efficient test development. Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing improved healthcare infrastructure and diagnostic capabilities, opening up new avenues for LDT adoption. Moreover, as demand grows for early disease detection and targeted therapies, LDTs are well-positioned to play a central role in niche diagnostic areas such as rare diseases and pharmacogenomics. Partnerships between academic research centers and commercial diagnostic companies can also accelerate LDT development and market reach.

Key Questions Answered in the Report:

  • What are the primary factors driving the global Laboratory Developed Test market's growth?
  • Which regions and application areas are experiencing the highest demand for LDTs?
  • How are technological innovations in molecular diagnostics shaping the LDT landscape?
  • Who are the key players in the Laboratory Developed Test market, and what strategies are they adopting to remain competitive?
  • What are the regulatory developments and future projections for the global LDT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Laboratory Developed Test market, such as Thermo Fisher Scientific Inc., QIAGEN, Roche Diagnostics, and Quest Diagnostics, are focusing on expanding their test portfolios, particularly in oncology, infectious diseases, and genetic testing. These companies are leveraging strategic collaborations with academic institutions, biotech firms, and healthcare providers to enhance innovation and accelerate time-to-market for novel assays. Investment in automation, AI-based data analysis tools, and next-generation sequencing technologies is enabling improved test accuracy and throughput. Furthermore, companies are engaging with regulatory bodies to ensure compliance and support smoother transitions under evolving LDT regulations.

Companies Covered in This Report:

  • Thermo Fisher Scientific Inc.
  • Kaneka Eurogentec S.A.
  • QIAGEN
  • Vastian
  • Roche Diagnostics
  • Adaptive Biotechnologies
  • Guardant Health, Inc.
  • Smiths Medical
  • Quest Diagnostics
  • Beckman Coulter
  • OPKO Health, Inc.

Laboratory Developed Test Market Segmentation:

By Test Type:

  • Clinical Biochemistry
  • Haematology
  • Immunology
  • Microbiology
  • Molecular Diagnostics
  • Others

By Application:

  • Oncology
  • Genetics
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

By End User:

  • Hospital Laboratories
  • Specialty Diagnostics Centers
  • Clinical Research Organizations
  • Research Institutes
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Laboratory Developed Test Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Reimbursement Scenario
  • 3.4. PESTLE Analysis
  • 3.5. Promotional Strategies, By Key Players

4. Global Laboratory Developed Test Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Laboratory Developed Test Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
      • 4.3.3.1. Clinical Biochemistry
      • 4.3.3.2. Hematology
      • 4.3.3.3. Immunology
      • 4.3.3.4. Microbiology
      • 4.3.3.5. Molecular Diagnostics
      • 4.3.3.6. Others
    • 4.3.4. Market Attractiveness Analysis: Test Type
  • 4.4. Global Laboratory Developed Test Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn), By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Oncology
      • 4.4.3.2. Genetics
      • 4.4.3.3. Infectious Diseases
      • 4.4.3.4. Autoimmune Disorders
      • 4.4.3.5. Other Conditions
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Laboratory Developed Test Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn), By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospital Laboratories
      • 4.5.3.2. Specialty Diagnostics Centers
      • 4.5.3.3. Clinical Research Organizations
      • 4.5.3.4. Research Institutes
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Laboratory Developed Test Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Laboratory Developed Test Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 6.4.1. Clinical Biochemistry
    • 6.4.2. Hematology
    • 6.4.3. Immunology
    • 6.4.4. Microbiology
    • 6.4.5. Molecular Diagnostics
    • 6.4.6. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Oncology
    • 6.5.2. Genetics
    • 6.5.3. Infectious Diseases
    • 6.5.4. Autoimmune Disorders
    • 6.5.5. Other Conditions
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospital Laboratories
    • 6.6.2. Specialty Diagnostics Centers
    • 6.6.3. Clinical Research Organizations
    • 6.6.4. Research Institutes
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Laboratory Developed Test Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 7.4.1. Clinical Biochemistry
    • 7.4.2. Hematology
    • 7.4.3. Immunology
    • 7.4.4. Microbiology
    • 7.4.5. Molecular Diagnostics
    • 7.4.6. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Oncology
    • 7.5.2. Genetics
    • 7.5.3. Infectious Diseases
    • 7.5.4. Autoimmune Disorders
    • 7.5.5. Other Conditions
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospital Laboratories
    • 7.6.2. Specialty Diagnostics Centers
    • 7.6.3. Clinical Research Organizations
    • 7.6.4. Research Institutes
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Laboratory Developed Test Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 8.4.1. Clinical Biochemistry
    • 8.4.2. Hematology
    • 8.4.3. Immunology
    • 8.4.4. Microbiology
    • 8.4.5. Molecular Diagnostics
    • 8.4.6. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Oncology
    • 8.5.2. Genetics
    • 8.5.3. Infectious Diseases
    • 8.5.4. Autoimmune Disorders
    • 8.5.5. Other Conditions
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospital Laboratories
    • 8.6.2. Specialty Diagnostics Centers
    • 8.6.3. Clinical Research Organizations
    • 8.6.4. Research Institutes
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Laboratory Developed Test Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 9.4.1. Clinical Biochemistry
    • 9.4.2. Hematology
    • 9.4.3. Immunology
    • 9.4.4. Microbiology
    • 9.4.5. Molecular Diagnostics
    • 9.4.6. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Oncology
    • 9.5.2. Genetics
    • 9.5.3. Infectious Diseases
    • 9.5.4. Autoimmune Disorders
    • 9.5.5. Other Conditions
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospital Laboratories
    • 9.6.2. Specialty Diagnostics Centers
    • 9.6.3. Clinical Research Organizations
    • 9.6.4. Research Institutes
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Laboratory Developed Test Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 10.4.1. Clinical Biochemistry
    • 10.4.2. Hematology
    • 10.4.3. Immunology
    • 10.4.4. Microbiology
    • 10.4.5. Molecular Diagnostics
    • 10.4.6. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Oncology
    • 10.5.2. Genetics
    • 10.5.3. Infectious Diseases
    • 10.5.4. Autoimmune Disorders
    • 10.5.5. Other Conditions
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospital Laboratories
    • 10.6.2. Specialty Diagnostics Centers
    • 10.6.3. Clinical Research Organizations
    • 10.6.4. Research Institutes
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Laboratory Developed Test Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 11.4.1. Clinical Biochemistry
    • 11.4.2. Hematology
    • 11.4.3. Immunology
    • 11.4.4. Microbiology
    • 11.4.5. Molecular Diagnostics
    • 11.4.6. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Oncology
    • 11.5.2. Genetics
    • 11.5.3. Infectious Diseases
    • 11.5.4. Autoimmune Disorders
    • 11.5.5. Other Conditions
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospital Laboratories
    • 11.6.2. Specialty Diagnostics Centers
    • 11.6.3. Clinical Research Organizations
    • 11.6.4. Research Institutes
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Test Types
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Thermo Fisher Scientific Inc.
      • 12.3.2.1. Overview
      • 12.3.2.2. Segments and Test Types
      • 12.3.2.3. Key Financials
      • 12.3.2.4. Market Developments
      • 12.3.2.5. Market Strategy
    • 12.3.3. Kaneka Eurogentec S.A.
      • 12.3.3.1. Overview
      • 12.3.3.2. Segments and Test Types
      • 12.3.3.3. Key Financials
      • 12.3.3.4. Market Developments
      • 12.3.3.5. Market Strategy
    • 12.3.4. Vastian
      • 12.3.4.1. Overview
      • 12.3.4.2. Segments and Test Types
      • 12.3.4.3. Key Financials
      • 12.3.4.4. Market Developments
      • 12.3.4.5. Market Strategy
    • 12.3.5. Roche Diagnostics
      • 12.3.5.1. Overview
      • 12.3.5.2. Segments and Test Types
      • 12.3.5.3. Key Financials
      • 12.3.5.4. Market Developments
      • 12.3.5.5. Market Strategy
    • 12.3.6. Adaptive Biotechnologies.
      • 12.3.6.1. Overview
      • 12.3.6.2. Segments and Test Types
      • 12.3.6.3. Key Financials
      • 12.3.6.4. Market Developments
      • 12.3.6.5. Market Strategy
    • 12.3.7. Guardant Health, Inc.
      • 12.3.7.1. Overview
      • 12.3.7.2. Segments and Test Types
      • 12.3.7.3. Key Financials
      • 12.3.7.4. Market Developments
      • 12.3.7.5. Market Strategy
    • 12.3.8. Smiths Medical
      • 12.3.8.1. Overview
      • 12.3.8.2. Segments and Test Types
      • 12.3.8.3. Key Financials
      • 12.3.8.4. Market Developments
      • 12.3.8.5. Market Strategy
    • 12.3.9. Quest Diagnostics
      • 12.3.9.1. Overview
      • 12.3.9.2. Segments and Test Types
      • 12.3.9.3. Key Financials
      • 12.3.9.4. Market Developments
      • 12.3.9.5. Market Strategy
    • 12.3.10. Beckman Coulter
      • 12.3.10.1. Overview
      • 12.3.10.2. Segments and Test Types
      • 12.3.10.3. Key Financials
      • 12.3.10.4. Market Developments
      • 12.3.10.5. Market Strategy
    • 12.3.11. OPKO Health, Inc.
      • 12.3.11.1. Overview
      • 12.3.11.2. Segments and Test Types
      • 12.3.11.3. Key Financials
      • 12.3.11.4. Market Developments
      • 12.3.11.5. Market Strategy
    • 12.3.12. Siemens Medical Solutions USA, Inc.
      • 12.3.12.1. Overview
      • 12.3.12.2. Segments and Test Types
      • 12.3.12.3. Key Financials
      • 12.3.12.4. Market Developments
      • 12.3.12.5. Market Strategy
    • 12.3.13. Quanterix
      • 12.3.13.1. Overview
      • 12.3.13.2. Segments and Test Types
      • 12.3.13.3. Key Financials
      • 12.3.13.4. Market Developments
      • 12.3.13.5. Market Strategy
    • 12.3.14. Proteomics International
      • 12.3.14.1. Overview
      • 12.3.14.2. Segments and Test Types
      • 12.3.14.3. Key Financials
      • 12.3.14.4. Market Developments
      • 12.3.14.5. Market Strategy

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations